KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report)'s stock price gapped up prior to trading on Monday . The stock had previously closed at $11.98, but opened at $14.02. KalVista Pharmaceuticals shares last traded at $14.02, with a volume of 3,560,127 shares traded.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on KALV shares. JMP Securities lifted their target price on KalVista Pharmaceuticals from $19.00 to $27.00 and gave the company a "market outperform" rating in a research note on Tuesday. Jones Trading restated a "buy" rating and set a $30.00 price target on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. Leerink Partners upped their price objective on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an "outperform" rating in a research report on Monday. Finally, HC Wainwright increased their price target on KalVista Pharmaceuticals from $20.00 to $27.00 and gave the stock a "buy" rating in a research report on Tuesday. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $26.29.
View Our Latest Report on KALV
KalVista Pharmaceuticals Stock Performance
The business has a fifty day moving average of $12.47 and a two-hundred day moving average of $11.11. The firm has a market cap of $743.31 million, a price-to-earnings ratio of -4.02 and a beta of -0.04.
Insider Buying and Selling at KalVista Pharmaceuticals
In other news, insider Paul K. Audhya sold 2,776 shares of the business's stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $11.84, for a total transaction of $32,867.84. Following the completion of the transaction, the insider directly owned 106,611 shares in the company, valued at approximately $1,262,274.24. The trade was a 2.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Benjamin L. Palleiko sold 7,169 shares of the company's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $14.50, for a total value of $103,950.50. Following the completion of the transaction, the chief executive officer directly owned 315,074 shares in the company, valued at $4,568,573. This represents a 2.22% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 15,899 shares of company stock worth $206,176. 10.50% of the stock is owned by insiders.
Institutional Investors Weigh In On KalVista Pharmaceuticals
A number of large investors have recently bought and sold shares of KALV. AlphaQuest LLC lifted its stake in shares of KalVista Pharmaceuticals by 17.1% in the fourth quarter. AlphaQuest LLC now owns 17,700 shares of the specialty pharmaceutical company's stock valued at $150,000 after buying an additional 2,588 shares during the period. Intech Investment Management LLC boosted its stake in KalVista Pharmaceuticals by 58.5% in the fourth quarter. Intech Investment Management LLC now owns 17,204 shares of the specialty pharmaceutical company's stock valued at $146,000 after acquiring an additional 6,349 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of KalVista Pharmaceuticals by 4.9% during the fourth quarter. Vanguard Group Inc. now owns 2,255,243 shares of the specialty pharmaceutical company's stock worth $19,102,000 after purchasing an additional 104,716 shares in the last quarter. Schroder Investment Management Group increased its stake in KalVista Pharmaceuticals by 86.8% in the 4th quarter. Schroder Investment Management Group now owns 805,445 shares of the specialty pharmaceutical company's stock valued at $6,758,000 after buying an additional 374,213 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in shares of KalVista Pharmaceuticals by 4.2% during the 4th quarter. Wellington Management Group LLP now owns 122,863 shares of the specialty pharmaceutical company's stock worth $1,041,000 after purchasing an additional 4,940 shares during the last quarter.
KalVista Pharmaceuticals Company Profile
(
Get Free Report)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
Featured Articles
Before you consider KalVista Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KalVista Pharmaceuticals wasn't on the list.
While KalVista Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.